These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1005 related articles for article (PubMed ID: 25727967)

  • 21. [Two new drugs for the treatment of idiopathic lung fibrosis: A new therapeutic era!].
    Crestani B
    Rev Med Interne; 2015 Nov; 36(11):719-21. PubMed ID: 26065328
    [No Abstract]   [Full Text] [Related]  

  • 22. Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
    Vega-Olivo M; Criner GJ
    Nurse Pract; 2018 May; 43(5):48-54. PubMed ID: 29465476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
    Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
    Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel therapies for idiopathic pulmonary fibrosis].
    Wand O; Kremer MR
    Harefuah; 2015 Jul; 154(7):446-50, 469, 468. PubMed ID: 26380465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
    Aryal S; Nathan SD
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological management of IPF.
    Borie R; Justet A; Beltramo G; Manali ED; Pradère P; Spagnolo P; Crestani B
    Respirology; 2016 May; 21(4):615-25. PubMed ID: 27072575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic advances in idiopathic pulmonary fibrosis.
    Fraser E; Hoyles RK
    Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
    Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pirfenidone in idiopathic pulmonary fibrosis.
    Maher TM
    Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials.
    Sgalla G; Lerede M; Richeldi L
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):93-101. PubMed ID: 33998354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving Survival in Idiopathic Pulmonary Fibrosis: The Race Has Just Begun.
    Collard HR
    Chest; 2017 Mar; 151(3):527-528. PubMed ID: 28279270
    [No Abstract]   [Full Text] [Related]  

  • 37. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [MODERN APPROACH TO THERAPY OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS].
    Tsvetkova OA; Voronkova OO; Buyanova OE
    Klin Med (Mosk); 2017; 95(3):281-5. PubMed ID: 30303652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
    Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
    Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
    Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
    Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.